Role of Progesterone Membrane Receptors in the Pathogenesis of Preeclampsia
Investigation of Progesterone Membrane Receptor Expression in Placental Tissue of Women With Preeclampsia and Their Potential Role in the Pathogenesis of Preeclampsia
Preeclampsia is a pregnancy-specific hypertensive disorder and remains a leading cause of maternal and perinatal morbidity and mortality worldwide. Although abnormal placentation, impaired trophoblast invasion, endothelial dysfunction, and immune dysregulation have been implicated in its pathogenesis, the underlying molecular mechanisms are not fully understood.
Progesterone plays a critical role in the maintenance of pregnancy through both classical nuclear receptors and membrane-associated progesterone receptors. Emerging evidence suggests that progesterone membrane receptors, including progesterone receptor membrane component 1 (PGRMC1), progesterone receptor membrane component 2 (PGRMC2), and members of the progestin and adipoQ receptor (PAQR) family, may regulate trophoblast invasion, placental development, and inflammatory responses.
This study aims to compare the placental expression levels of PGRMC1, PGRMC2, and PAQR family receptors between women with preeclampsia and healthy pregnant controls and to investigate their potential role in the pathophysiology of preeclampsia.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Preeclampsia affects approximately 3-8% of pregnancies and is characterized by new-onset hypertension and multisystem involvement after 20 weeks of gestation. Despite extensive research, its molecular pathogenesis remains incompletely understood.
Progesterone is essential for successful pregnancy maintenance and contributes to uterine quiescence, trophoblast function, and maternal-fetal immune tolerance. In addition to classical genomic signaling pathways, progesterone exerts rapid non-genomic effects through membrane-associated receptors, including PGRMC1, PGRMC2, and PAQR family members.
Recent studies have demonstrated that these receptors are involved in trophoblast invasion, angiogenesis, endothelial function, and inflammatory regulation. Alterations in their expression may contribute to abnormal placentation and endothelial dysfunction observed in preeclampsia.
The present study will evaluate placental expression levels of PGRMC1, PGRMC2, and selected PAQR family receptors in women with preeclampsia and healthy controls. Placental tissue obtained after delivery will undergo immunohistochemical and mRNA expression analyses. The findings may improve understanding of the molecular mechanisms underlying preeclampsia and identify potential biomarkers or therapeutic targets.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Canan Soyer Çalışkan, MD, Associate Professor
- Numéro de téléphone: + 90 532 203 55 38
- E-mail: canan.caliskan@samsun.edu.tr
Sauvegarde des contacts de l'étude
- Nom: Canan Soyer Çalışkan, MD, Associate Professor
- Numéro de téléphone: 90 532 203 55 90 362 311 15 40
- E-mail: canan.caliskan@samsun.edu.tr
Lieux d'étude
-
-
-
Samsun, Turquie (Türkiye)
- Recrutement
- Samsun University Faculty of Medicine Samsun Training and Research Hospital
-
Contact:
- Canan SOYER ÇALIŞKAN, MD, Associated Professor
- Numéro de téléphone: +90 532 203 55 38
- E-mail: canan.caliskan@samsun.edu.tr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
Preeclampsia Group Pregnant women diagnosed with preeclampsia who provide placental tissue samples following delivery.
Healthy Control Group Normotensive pregnant women providing placental tissue samples following delivery.
La description
Inclusion Criteria:
Preeclampsia Group Women aged 18-45 years Singleton pregnancy Diagnosis of preeclampsia according to ACOG criteria Delivery at the study center Written informed consent Control Group Women aged 18-45 years Singleton pregnancy Normotensive healthy pregnancy Delivery at the study center Written informed consent
Exclusion Criteria:
Age <18 or >45 years Multiple gestation Fetal structural or chromosomal anomalies Chronic hypertension Pre-existing diabetes mellitus Autoimmune diseases Renal disease Other major systemic disorders
-
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
preeclampsia group
Preeclampsia group
|
|
Control Group
Healty Control Group
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Placental expression levels of progesterone membrane receptors (PGRMC1, PGRMC2, and PAQR family receptors)
Délai: At delivery
|
Quantitative comparison of placental receptor expression levels between preeclamptic and healthy pregnancies using immunohistochemical and mRNA-based analyses.
|
At delivery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Canan Soyer Çalışkan, MD, Associate Professor, Samsun University Faculty of Medicine, Samsun Training and Research Hospital
- Chaise d'étude: Soyer Çalışkan, Samsun University Faculty of Medicine, Samsun Training and Research Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- OMUK2025/311
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .